Form 4 for GILD Gilead Sciences
Accepted 2025-05-23 00:00:00 ET · period of report 2025-05-22 · accession 0001127602-25-015457 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-05-23 | 2025-05-22 | GILD | Mercier Johanna | Chief Commercial Off | M - OptEx | $66.64 | +25.0K | 136.7K | +22% | +$1.67M |
| DM | 2025-05-23 | 2025-05-22 | GILD | Mercier Johanna | Chief Commercial Off | S - Sale+OE | $107.52 | -28.0K | 124.2K | -18% | -$3.01M |
| DM | 2025-05-23 | 2025-05-22 | GILD | Mercier Johanna | Chief Commercial Off | M - OptEx | $0.00 | -25.0K | 135.6K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-22 | M | A | 12,500 | $66.64 | 136,652 | D | — | — | |
| 2 | Common | Common Stock | 2025-05-22 | S | D | 12,500 | $107.52 | 124,152 | D | — | — | (F2) Sale prices reported for the transactions reported here range from $107.06 to $107.95. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 3 | Common | Common Stock | 2025-05-22 | S | D | 3,000 | $107.52 | 121,152 | D | — | — | (F4) Sale prices reported for the transactions reported here range from $107.16 to $107.87. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 4 | Common | Common Stock | 2025-05-22 | S | D | 12,500 | $107.52 | 124,152 | D | — | — | (F3) Sale prices reported for the transactions reported here range from $106.96 to $107.95. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 5 | Common | Common Stock | 2025-05-22 | M | A | 12,500 | $66.64 | 136,652 | D | — | — | |
| 6 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-05-22 | M | D | 12,500 | $0.00 | 123,110 | D | $66.64 · — to 2029-07-24 | 12,500 Common Stock | (F5) The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-05-22 | M | D | 12,500 | $0.00 | 135,610 | D | $66.64 · — to 2029-07-24 | 12,500 Common Stock | (F5) The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |